<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(18)</volume><submitter>Isaacs JT</submitter><funding>NCI NIH HHS</funding><journal>Cell cycle (Georgetown, Tex.)</journal><pagination>1639-1640</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5602292</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.</pubmed_title><pmcid>PMC5602292</pmcid><funding_grant_id>R01 CA184012</funding_grant_id><pubmed_authors>Isaacs JT</pubmed_authors><pubmed_authors>Denmeade SR</pubmed_authors><pubmed_authors>Brennen WN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.</name><description/><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2025-05-29T16:29:53.461Z</modification><creation>2025-04-04T07:42:26.884Z</creation></dates><accession>S-EPMC5602292</accession><cross_references><pubmed>28820291</pubmed><doi>10.1080/15384101.2017.1360645</doi></cross_references></HashMap>